BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 20071853)

  • 1. Varenicline: for smoking cessation.
    Rao J; Shankar PK
    Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of varenicline for smoking cessation].
    Christalla P; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
    King DP; Paciga S; Pickering E; Benowitz NL; Bierut LJ; Conti DV; Kaprio J; Lerman C; Park PW
    Neuropsychopharmacology; 2012 Feb; 37(3):641-50. PubMed ID: 22048466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
    West R; Baker CL; Cappelleri JC; Bushmakin AG
    Psychopharmacology (Berl); 2008 Apr; 197(3):371-7. PubMed ID: 18084743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006103. PubMed ID: 17253581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
    Foulds J
    Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varenicline: new treatment with efficacy in smoking cessation.
    Reus VI; Obach RS; Coe JW; Faessel H; Rollema H; Watsky E; Reeves K
    Drugs Today (Barc); 2007 Feb; 43(2):65-75. PubMed ID: 17353944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
    Doggrell SA
    Expert Opin Pharmacother; 2007 Dec; 8(17):2903-15. PubMed ID: 18001252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varenicline: progress in smoking cessation treatment.
    Glover ED; Rath JM
    Expert Opin Pharmacother; 2007 Aug; 8(11):1757-67. PubMed ID: 17685891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.
    Xenakis JG; Kinter ET; Ishak KJ; Ward AJ; Marton JP; Willke RJ; Davies S; Caro JJ
    Pharmacoeconomics; 2011 Jun; 29(6):497-510. PubMed ID: 21452908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [On oral medications, especially varenicline].
    Kurioka N
    Nihon Rinsho; 2013 Mar; 71(3):487-92. PubMed ID: 23631241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-nicotinic therapies for smoking cessation.
    Siu EC; Tyndale RF
    Annu Rev Pharmacol Toxicol; 2007; 47():541-64. PubMed ID: 17209799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.